Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NYSE
IPO Date: March 15, 2018
Headquarters: 3928 Point Eden Way, Hayward, CA, United States, 94545
Founder-Led: Yes — Terry Rosen (Co-Founder, Chairman & CEO), Juan Jaen (Co-Founder & President)
Key Metrics
Current Price
$28.92
Market Cap
$3.77B
Float
88.9M
Shares Outstanding
125.8M
Price/Sales (TTM)
15.97
vs. Analyst Target
+23.6% to analyst PT
Profit Margin
-156.36%
Operating Margin (TTM)
-788.24%
Revenue (TTM)
$236M
Dividend Rate
None
Analyst Target Price
$35.75 (13 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$78.0M
-$123M
$78.0M
-$120M
2021
$383M
$53.0M
$383M
$59.0M
2022
$112M
-$267M
$112M
-$258M
2023
$117M
-$307M
$117M
-$291M
2024
$258M
-$283M
$258M
-$269M
2025
$247M
-$353M
$237M
-$335M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Jun 2025
$160M
-$8.0M
Sep 2025
$26.0M
-$135M
Dec 2025
$33.0M
-$98.0M
Mar 2026
$17.0M
-$128M
Ownership & Float
Insider Ownership
29.2%
Institutional Ownership
72.4%
Short Float
14.9%
% of All Funds Holding
2.34%
Number of Funds Holding
192
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$25.95
Near-term / short-term trend
Weekly
40-Week SMA
$22.56
Medium-term trend
Weekly
80-Week SMA
$16.44
Cyclical trend (business cycle)
Weekly
200-Week SMA
$17.87
Secular trend (multi-year)
Monthly
10-Month SMA
$24.32
Near-term monthly trend
Monthly
20-Month SMA
$17.45
Medium-term monthly trend
Monthly
40-Month SMA
$17.35
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$25.40
support
1.19x
0 months ago
$20.00
support
1.45x
7 months ago
$13.50
support
1.60x
8 months ago
Historical Earnings Reactions (34 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.54%
0.49%
55.88%
11.14%
-8.37%
1 Day
1.58%
-0.34%
47.06%
19.87%
-10.56%
1 Week
2.21%
-0.20%
50.00%
20.56%
-14.00%
2 Weeks
2.21%
-1.49%
50.00%
39.52%
-45.37%
1 Month
5.61%
4.08%
69.70%
40.34%
-24.97%
Next earnings: August 5, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-6.2%
25.0%
8
Feb
12.9%
62.5%
8
Mar
-7.7%
37.5%
8
Apr
8.0%
44.4%
9
May
-2.5%
44.4%
9
Jun
0.7%
44.4%
9
Jul
1.5%
50.0%
8
Aug
6.2%
62.5%
8
Sep
2.4%
50.0%
8
Oct
1.4%
37.5%
8
Nov
17.8%
87.5%
8
Dec
-2.8%
25.0%
8
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.07%
48.1%
393
Tuesday
-0.02%
48.1%
430
Wednesday
0.14%
49.5%
426
Thursday
0.41%
47.7%
419
Friday
0.22%
48.6%
418
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 72.4%
Insider Transactions — Smart Summary
Total insider ownership: 29.2%
Founder-led management: Terry Rosen (Co-Founder, Chairman & CEO), Juan Jaen (Co-Founder & President)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Arcus Biosciences Inc
(RCUS) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.